title: [Clinical diagnosis, treatment and prognosis of elderly SARS patients].
abstract: OBJECTIVE
  To discuss the clinical manifestations, therapeutic strategy and prognosis of patients with severe acute respiratory syndrome (SARS) older than 60 years.
  
  
  METHODS
  Elderly patients diagnosed as SARS in Peking Union Medical College Hospital were compared with younger patients.
  
  
  RESULTS
  Twenty-four elderly patients and 53 younger patients were analysed. Elderly patients had more coexisting conditions, such as hypertension, diabetes, coronary heart disease, and renal disease than control group (P < 0.05). Rate of respiratory failure in elderly patients was higher than that in control group (P < 0.05). Elderly patients had more respiratory symptoms, such as cough, sputum, and shortness of breath (P < 0.05). Rate of lymphocytopenia and thrombocytopenia in elderly patients was higher than that in control group. All patients were given ribavirin and antibiotics. More patients in elderly group were given 3rd generation cephalosporin and imipenem. Mortality rate in elderly group was higher than that in control group (33.3% vs 3.8%, P < 0.05). Univariate analysis showed that age, respiratory failure, and thrombocytopenia were risk factors of death, but logistic analysis did not find any independent risk factor.
  
  
  CONCLUSIONS
  Though the elderly patients have a lower morbidity of SARS, they have more coexisting conditions. The therapy of elderly patients is more difficult than that of control group, and the mortality in elderly patients is high.
authors.affiliation: Department of Respiratory Diseases, PUMC Hospital, CAMS and PUMC, Beijing 100730, China. caobin1999@yahoo.com
authors.forename: Bin
authors.initials: B
authors.lastname: Cao
authors.forename: Zheng-yin
authors.initials: ZY
authors.lastname: Liu
authors.forename: Meng-zhao
authors.initials: MZ
authors.lastname: Wang
authors.forename: Bai-qiang
authors.initials: BQ
authors.lastname: Cai
authors.forename: Zuo-jun
authors.initials: ZJ
authors.lastname: Xu
authors.forename: Yan
authors.initials: Y
authors.lastname: Bai
authors.forename: Yuan-jue
authors.initials: YJ
authors.lastname: Zhu
authors.forename: Wen-bing
authors.initials: WB
authors.lastname: Xu
authors.forename: Wei-xuan
authors.initials: WX
authors.lastname: Lu
authors.forename: Long-yun
authors.initials: LY
authors.lastname: Li
authors.forename: Tai-sheng
authors.initials: TS
authors.lastname: Li
authors.forename: Zhong
authors.initials: Z
authors.lastname: Wang
mesh_terms: D000367:Age Factors; D000368:Aged; D000998:Antiviral Agents / Q000627:therapeutic use*; D048909:Diabetes Complications; D005260:Female; D006801:Humans; D006973:Hypertension / Q000150:complications; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012189:Retrospective Studies; D012254:Ribavirin / Q000627:therapeutic use*; D012307:Risk Factors; D045169:Severe Acute Respiratory Syndrome / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy
chemical_list: D000998:Antiviral Agents; D012254:Ribavirin